Chemistry:Ruvonoflast

From HandWiki

Ruvonoflast is an investigational new drug that is being evaluated by Nodthera for the treatment of obesity in patients with high cardiovascular risk. It is an NLRP3 inflammasome inhibitor.[1][2]

References

  1. ↑ "NT 0796". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800064500. 
  2. ↑ "Anti-Inflammatory Effects of Oral NLRP3 Inhibition With Ruvonoflast Among Individuals at Elevated Cardiovascular Risk". Journal of the American College of Cardiology: S0735–1097(26)06570–8. May 2026. doi:10.1016/j.jacc.2026.05.014. PMID 42187339.